New drug combination for NK/T-cell lymphoma with immune complications
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with extranodal NK/T-cell lymphoma confirmed by biopsy
- Meet at least 5 criteria for hemophagocytic lymphohistiocytosis (a condition where immune cells attack your own blood cells)
- Age 18 or older
- Healthy heart function with ejection fraction of 50% or higher
- No active bleeding, uncontrolled infections, or other cancers
- Negative for HIV, hepatitis C (or controlled if positive), and hepatitis B (or very low viral load if positive)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
This study tests a new medicine called sugemalimab (an immunotherapy that helps your immune system fight cancer) combined with a chemotherapy regimen (PGemOx) for people with a rare type of lymphoma that has come back or not responded to previous treatment. The study could help you see if this combination works better than the placebo (inactive) plus the same chemotherapy.
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.